



Meeting documents and Share Purchase Plan Offer document

For Immediate Release:

June 26, 2014

Sydney, Australia – Simavita Limited (“**Simavita**” or the “**Company**”) (TSXV: SV; ASX: SVA) is pleased to release the Notice and accompanying Management Information Circular in respect of a Special Meeting of shareholders of the Company that will be held at 10:00 am (Australian Eastern Standard time) on Wednesday, July 23, 2014 at the Company’s offices on Level 13, 54 Miller Street, North Sydney NSW 2060 Australia. Samples of the proxy forms that will be sent to the holders of the Company’s shares and CDIs are also attached.

The Company is also pleased to release the Offer document in respect of its Share Purchase Plan which opens today. A sample of the application form that will be sent to eligible participants is also attached.

Copies of all documents will be mailed to eligible recipients in the coming days.

For further information, please check our website (www.simavita.com) or contact the persons outlined below.

Company	Media and Investor Relations
Philippa Lewis, Chief Executive Officer T: +61 2 8405 6381	Buchan Consulting Jane Lowe E: jlowe@buchanwe.com.au T: +61 2 9237 2800
Tom Howitt, Company Secretary T: +61 2 8405 6391	

About Simavita

Simavita is a medical device company that has developed an innovative, world first solution for the management of urinary incontinence, with a focus on the elderly. The first product is the SIM™ platform technology which is an instrumented incontinence assessment application that provides evidence-based incontinence management care plans to the residential aged care market.

About SIM™

SIM™ is a wireless sensor technology that delivers evidence-based instrument incontinence data on individuals. SIM™ provides user friendly tools and software to assess the incontinence condition and to help plan better outcomes. SIM™ is used to detect, record and report incontinence events during a compulsory or recommended assessment period in residential aged care facilities to develop an evidence-based incontinence care plan.

Conducting assessments is mandatory in many countries and the incontinence assessment creates an influential element of care of each individual. For more information on Simavita or SIM™, please visit www.simavita.com.

The TSX Venture Exchange has in no way passed upon the merits of the transactions set out herein and has neither approved nor disapproved the contents of this press release. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this Release.

Forward-Looking Information

This document may contain “forward-looking information” within the meaning of Canadian securities laws (“**forward-looking information**”). This forward-looking information is given as of the date of this document.

Forward-looking information relates to future events or future performance and reflects Simavita management’s expectations or beliefs regarding future events and includes, but is not limited to, information with respect to the successful completion of the Private Placement and SPP. Assumptions upon which such forward-looking information is based include that Simavita will be able to successfully execute on its business plans. Many of these assumptions are based on factors and events that are not within the control of Simavita and there is no assurance they will prove to be correct.

In certain cases, forward-looking information can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “potential”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or information that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved” or the negative of these terms or comparable terminology. By its very nature forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Simavita to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. Such factors include, among others, risks related to actual results of current business activities; changes in business plans and strategy as plans continue to be refined; other risks of the medical devices and technology industry; delays in obtaining governmental approvals or financing or in the completion of development activities; as well as those factors detailed from time to time in Simavita’s interim and annual financial statements and management’s discussion and analysis of those statements. Although Simavita has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. Simavita provides no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers should not place undue reliance on forward-looking information.



SIMAVITA LIMITED

NOTICE OF SPECIAL MEETING OF SHAREHOLDERS

TAKE NOTICE that a special meeting of the shareholders of Simavita Limited (the “**Corporation**”) will be held at the office of the Corporation at Level 13, 54 Miller Street, North Sydney NSW 2060, Australia on Wednesday, July 23, 2014, at 10:00 a.m. (Australian Eastern Standard time) or at any adjournment or postponement thereof for the purposes of:

- (a) Resolution #1: considering, and if deemed advisable, passing, with or without variation, an ordinary resolution approving and ratifying, for the purposes of ASX Listing Rule 7.4 and all other purposes, the prior issue to professional and sophisticated investors of 6,886,673 common shares in the capital of the Corporation at an issue price of AUD\$0.45 per share, and otherwise as more particularly described in the accompanying management information circular;
- (b) Resolution #2: approving and authorizing, for the purposes of the ASX Listing Rule 10.11 and all other purposes, the issue to Dussman Pty. Ltd. (an entity associated with Mr. Damien Haakman) of 6,168,880 common shares in the capital of the Corporation at an issue price of AUD\$0.45 per share, and otherwise as more particularly described in the accompanying management information circular;
- (c) Resolution #3: approving and authorizing, for the purposes of the ASX Listing Rule 10.11 and all other purposes, the issue to Ms. Philippa Lewis (and/or associates and affiliates of hers) of 111,112 common shares in the capital of the Corporation at an issue price of AUD\$0.45 per share, and otherwise as more particularly described in the accompanying management information circular;
- (d) Resolution #4: approving and authorizing, for the purposes of the ASX Listing Rule 10.11 and all other purposes, the issue to Mr. Peter Cook (and/or associates and affiliates of his) of 111,112 common shares in the capital of the Corporation at an issue price of AUD\$0.45 per share, and otherwise as more particularly described in the accompanying management information circular;
- (e) Resolution #5: approving and authorizing, for the purposes of the ASX Listing Rule 10.11 and all other purposes, the issue to Mr. Ari Bergman (and/or associates and affiliates of his) of 111,112 common shares in the capital of the Corporation at an issue price of AUD\$0.45 per share, and otherwise as more particularly described in the accompanying management information circular; and
- (f) transacting such further and other business as may properly come before the said meeting or any adjournment or postponement thereof.

Specific details of the above items of business are contained in the information circular of management which accompanies this notice of meeting and, together with management's form of proxy and a CDI Voting Instruction Form, which also accompanies this notice of meeting, form a part hereof and must be read in conjunction with this notice of meeting. Shareholders of record at the close of business on Thursday, June 12, 2014 are entitled to notice of, to attend and vote at the meeting either in person or by proxy.

A form of proxy will not be valid for the meeting or any adjournment or postponement thereof unless it is completed by the shareholder or by his attorney authorized in writing and must be delivered to: Computershare Investor Services, at 8th Floor, 100 University Avenue, Toronto, Ontario M5J 2Y1 Canada, fax number +1 866 249 7775 (toll-free North America) or fax number +1 416 263 9524 (America) not later than forty-eight (48) hours (excluding Saturdays, Sundays and statutory holidays in the Province of British Columbia) prior to the time set for the meeting or any adjournment or postponement thereof.

Holders of CHESS Depository Interests ("CDIs") are invited to attend the meeting. CDI holders must complete, sign and return the enclosed CDI Voting Instruction Form to Computershare Investor Services Pty. Limited, GPO Box 242, Melbourne, Victoria 3001 Australia (the number to fax CDI Voting Instruction Forms within Australia is (03) 9473 2555 and outside Australia is +61 3 9473 2555) so that each CDI holder may elect to direct CHESS Depository Nominees Pty. Ltd. ("CDN") to vote the relevant underlying common shares on his or her behalf or instruct CDN to appoint such CDI holder or his or her nominee as proxy to vote the common shares underlying the CDIs in person at the meeting. In either case, the CDI Voting Instructions Form needs to be received at the address shown on the CDI Voting Instructions Form not later than forty-eight (48) hours (excluding Saturdays, Sundays and statutory holidays in Australia) prior to the time set for the meeting or any adjournment or postponement thereof.

DATED: June 25, 2014

By Order of the Board of Directors

(Signed) "Philippa Lewis"

**Philippa M. Lewis
Chief Executive Officer and Executive Director**



SIMAVITA LIMITED
INFORMATION CIRCULAR
(as at June 25, 2014)
FOR THE SPECIAL MEETING OF SHAREHOLDERS
TO BE HELD ON WEDNESDAY, JULY 23, 2014
PROXY SOLICITATION

PURPOSE OF SOLICITATION

This management information circular (the “**Information Circular**”) is furnished in connection with the solicitation of proxies by the management of Simavita Limited (the “**Corporation**”) for use at the special meeting of common shareholders of the Corporation, to be held at the office of the Corporation at Level 13, 54 Miller Street, North Sydney NSW 2060, Australia on Wednesday, July 23, 2014, at 10:00 a.m. (Australian Eastern Standard time) or at any adjournment or postponement thereof for the purposes set out in the accompanying notice of meeting (the “**Meeting**”).

The cost of such solicitation will be borne by the Corporation and will be made primarily by mail. Directors and officers of the Corporation may without special compensation solicit proxies by telephone, facsimile or in person.

In this Information Circular, unless otherwise stated, references to “\$” are to amounts in Australian dollars.

APPOINTMENT AND REVOCATION OF PROXIES

The persons named in the enclosed form of proxy are directors and officers of the Corporation and are nominees of management. Shareholders have the right to appoint a nominee (who need not be a shareholder) to represent them at the Meeting other than the persons designated in the enclosed form of proxy, and may do so by inserting the name of the appointed representative in the blank space provided in the form of proxy.

A form of proxy will not be valid for the Meeting or any adjournment or postponement thereof unless it is completed by the shareholder or by his or her attorney authorized in writing and must be delivered to: Computershare Investor Services, at 8th Floor, 100 University Avenue, Toronto, Ontario M5J 2Y1 Canada, fax number +1 866 249 7775 (toll-free North America) or fax number +1 416 263 9524 (North America), not later than forty-eight (48) hours (excluding Saturdays, Sundays and statutory holidays in the Province of British Columbia, Canada) prior to the time set for the Meeting or any adjournment or postponement thereof.

In addition to revocation in any other manner permitted by law, a shareholder who has given a proxy may revoke it as to any matter upon which a vote has not already been cast pursuant to the authority conferred by the proxy. A proxy may be revoked by either executing a proxy bearing a later date or by executing a valid notice of revocation, either of the foregoing to be executed by the shareholder or by his or her authorized attorney in writing, or, if the shareholder is a corporation, under its corporate seal by an officer or attorney duly authorized, and by depositing the proxy bearing a later date with Farris, Vaughan, Wills & Murphy, LLP (Attn: Denise C. Nawata) located at 700 West Georgia Street, 25th Floor, Vancouver, British

Columbia, V7Y 1B3, Canada, not later than forty-eight (48) hours (excluding Saturdays, Sundays and statutory holidays in the Province of British Columbia, Canada) prior to the time set for the Meeting or any adjournment or postponement at which the proxy is to be used, or by depositing the revocation of proxy with the chairman of such meeting on the day of the meeting, or any adjournment or postponement of the Meeting.

VOTING SHARES

The Corporation is authorized to issue an unlimited number of common shares without par value. As of June 24, 2014, 58,766,653 common shares without par value were issued and outstanding. Of the 58,766,653 common shares issued and outstanding on June 24, 2014, 20,283,311 common shares were held by CHESS Depository Nominees Pty. Ltd. (“CDN”), a wholly-owned subsidiary of the Australian Securities Exchange (the “ASX”), on behalf of holders of CHESS Depository Interests (“CDIs”). CDN has issued CDIs that represent beneficial interests in the common shares held by CDN. CDIs are traded on the electronic transfer and settlement operated by the ASX.

All references in this Information Circular to outstanding common shares include common shares held by CDN and all references to holders of common shares include CDI holders.

Each common share entitles the holder to one vote on all matters to come before the Meeting. No group of shareholders has the right to elect a specified number of directors, nor are there cumulative or similar voting rights attached to the common shares of the Corporation. There are no other classes of voting securities of the Corporation outstanding.

The quorum for the Meeting is two persons who are, or who represent by proxy, shareholders who, in the aggregate, hold at least 5% of the issued shares entitled to be voted at the Meeting.

The Corporation has fixed Thursday, June 12, 2014 as the record date for determination of the persons entitled to receive notice of and vote at the Meeting. Only a shareholder of record as of the record date is entitled to receive notice of and vote at the Meeting.

VOTING OF PROXIES

This section only applies to the holders of common shares of the Corporation that are not represented by CDIs. Holders of CDIs should refer to the section in this Information Circular headed “*CDI Holders May Give Direction to CDN*”.

The persons named in the enclosed form of proxy are directors and/or officers of the Corporation and have indicated their willingness to represent the shareholder who appoints them as proxy. Each shareholder may instruct his proxy how to vote his common shares by completing the enclosed form of proxy.

The person indicated in the enclosed form of proxy shall vote the common shares in respect of which they are appointed in accordance with the direction of the shareholder appointing them.

In the event of an absence of direction to vote the common shares in respect of which they are appointed, the management appointees named in the accompanying proxy will vote such common shares in favour of:

- I. **Resolution #1: approving and ratifying, for the purposes of ASX Listing Rule 7.4 and all other purposes, the prior issue to professional and sophisticated investors of a total of 6,886,673 common shares in the capital of the Corporation at an issue price of AUD\$0.45 per share;**

- II. **Resolution #2:** approving and authorizing, for the purposes of the ASX Listing Rule 10.11 and all other purposes, the issue to Dussman Pty. Ltd. (an entity associated with Mr. Damien Haakman) of 6,168,880 common shares in the capital of the Corporation at an issue price of AUD\$0.45 per share;
- III. **Resolution #3:** approving and authorizing, for the purposes of the ASX Listing Rule 10.11 and all other purposes, the issue to Ms. Philippa Lewis (and/or associates and affiliates of hers) of 111,112 common shares in the capital of the Corporation at an issue price of AUD\$0.45 per share;
- IV. **Resolution #4:** approving and authorizing, for the purposes of the ASX Listing Rule 10.11 and all other purposes, the issue to Mr. Peter Cook (and/or associates and affiliates of his) of 111,112 common shares in the capital of the Corporation at an issue price of AUD\$0.45 per share;
- V. **Resolution #5:** approving and authorizing, for the purposes of the ASX Listing Rule 10.11 and all other purposes, the issue to Mr. Ari Bergman (and/or associates and affiliates of his) of 111,112 common shares in the capital of the Corporation at an issue price of AUD\$0.45 per share; and
- VI. transacting such further and other business as may properly come before the Meeting or any adjournment or postponement thereof.

THE ENCLOSED FORM OF PROXY CONFERS DISCRETIONARY AUTHORITY UPON THE PERSON INDICATED IN THE PROXY WITH RESPECT TO AMENDMENTS OR VARIATIONS TO MATTERS IDENTIFIED IN THE NOTICE OF SPECIAL MEETING OF SHAREHOLDERS (THE “NOTICE”) AND WITH RESPECT TO OTHER MATTERS WHICH MAY PROPERLY COME BEFORE THE MEETING. At the time of printing of the Information Circular, management of the Corporation knows of no such amendments, variations or other matters to come before the Meeting other than the matters referred to in the Notice and the Information Circular. If any matters which are not now known to the directors and executive officers of the Corporation should properly come before the Meeting, the persons named in the accompanying form of proxy will vote on such matters in accordance with their best judgment.

ADVICE TO BENEFICIAL SHAREHOLDERS

The information set forth in this section is of significant importance to many shareholders of the Corporation, as a substantial number of shareholders do not hold common shares in their own name. Shareholders who do not hold their common shares in their own name (referred to in this Information Circular as “**Beneficial Shareholders**”) should note that only proxies deposited by shareholders whose names appear on the records of the Corporation as the registered holders of common shares can be recognized and acted upon at the Meeting. If common shares are listed in an account statement provided to a shareholder by a broker, then, in almost all cases, those common shares will not be registered in the shareholder’s name on the records of the Corporation. Such common shares will more likely be registered under the name of the shareholder’s broker or an agent of that broker. In Canada, the vast majority of such common shares are registered under the name of CDS & Co. (the registration name for The Canadian Depositary for Securities, which acts as nominee for many Canadian brokerage firms). Common shares held by brokers or their agents or nominees can only be voted (for or against resolutions) upon the instructions of the Beneficial Shareholder. Without specific instructions, a broker and its agents and nominees are prohibited from voting shares for the broker’s clients.

Therefore, Beneficial Shareholders should ensure that instructions respecting the voting of their common shares are communicated to the appropriate person.

The Corporation does not know for whom the common shares registered to CDS & Co. are held. Therefore, Beneficial Shareholders cannot be recognized by the Corporation at the Meeting. In order to ensure that their common shares are voted at the Meeting, Beneficial Shareholders should carefully follow instructions received from their broker or intermediary. Often, the form of proxy supplied to Beneficial Shareholders by their brokers is identical to that provided to registered shareholders, however, its purpose is limited to instructing the brokers/registered shareholder how to vote on behalf of the Beneficial Shareholder, and it is often referred to as a voting instruction form (“**VIF**”). The majority of the brokers now delegate the job of obtaining instructions from clients and voting shares according to their client’s instructions to a corporation named Broadridge Financial Solutions, Inc. (“**Broadridge**”). Broadridge mails a VIF to Beneficial Shareholders in lieu of the form of proxy provided by the Corporation. The VIF will name the same individuals as the Corporation’s form of proxy to represent Beneficial Shareholders at the Meeting. Beneficial Shareholders have the right to appoint a person (who need not be a shareholder of the Corporation) other than the individuals designated in the VIF, to represent Beneficial Shareholders at the Meeting. To exercise this right, Beneficial Shareholders should insert the name of their desired representative in the blank space provided in the VIF. The completed VIF must then be returned to Broadridge by mail or facsimile or given to Broadridge by phone or over the internet, in accordance with Broadridge’s instructions. Broadridge then tabulates the results of all instructions received and completed in accordance with the instructions provided on the enclosed VIF and provides appropriate instructions respecting the voting of common shares of the Corporation to be represented at the Meeting. **If a Beneficial Shareholder receives a VIF from Broadridge, the VIF cannot be used to vote common shares of the Corporation directly at the Meeting – the VIF must be completed and returned to Broadridge, in accordance with its instructions, well in advance of the Meeting in order to have common shares of the Corporation voted.**

All references to shareholders in this Information Circular, the accompanying instrument of proxy and Notice are to shareholders of record unless specifically stated otherwise.

The Corporation is not sending proxy-related materials to registered holders or beneficial holders using notice-and-access, as such term is defined in National Instrument 54-101 – *Communication with Beneficial Owners of Securities of a Reporting Issuer* (“**NI 54-101**”). The Corporation is sending proxy related materials directly to non-objecting beneficial owners under NI 54-101.

CDI HOLDERS MAY GIVE DIRECTIONS TO CDN

The Corporation will permit CDI holders to attend the Meeting.

Each CDI holder has the right to:

- (a) direct CDN how to vote in respect of their CDIs; or
- (b) instruct CDN to appoint the CDI holder or a person nominated by the holder as the holder’s proxy for the purposes of attending and voting at the Meeting.

If you are a CDI holder and you wish to direct CDN how to vote in respect of your CDIs or appoint yourself or a nominee as your proxy, you should read, complete, date and sign the accompanying CDI voting instruction form and deposit it with Computershare Investor Services Pty. Limited, GPO Box 242, Melbourne, Victoria 3001 Australia (the number to fax CDI Voting Instruction Forms within Australia is (03) 9473 2555 and outside Australia is +61 3 9473 2555) not less than forty-eight (48) hours (excluding

Saturdays, Sundays and statutory holidays in Australia) prior to the time set for the Meeting or any adjournment or postponement at which the proxy is to be used.

PRINCIPAL HOLDERS OF VOTING SHARES

At June 24, 2014, the Corporation had 58,766,653 common shares issued and outstanding. To the knowledge of the directors and executive officers of the Corporation, as of the date of this Information Circular, no person or company beneficially owns, or controls or directs, directly or indirectly, voting shares of the Corporation carrying more than ten percent (10%) of the voting rights attached to all of the issued and outstanding common shares of the Corporation other than the following:

Name of Shareholder	Number of Common Shares Beneficially Owned, or Controlled or Directed, Directly or Indirectly	Percentage of Outstanding Common Shares
Dussman Pty. Ltd.	24,938,827	42.4%

PARTICULARS OF MATTERS TO BE ACTED UPON AT THE MEETING

The Corporation announced on June 18, 2014 in Canada (June 19, 2014 in Australia) the proposed allotment of up to a maximum of 8,800,000 common shares of the Corporation to be issued at a price of \$0.45 per common share prior to this special meeting being held. The final proceeds raised for this first issuance was announced on June 22, 2014 in Canada (June 23, 2014 in Australia) of \$3,009,003, issuing a total of 6,886,673 common shares of the Corporation (the “**First Tranche**”) (being the subject of Resolution #1); and subject to shareholder approval, a proposed allotment of up to a maximum of 6,502,216 common shares of the Corporation issued at a price of \$0.45 per share (the “**Second Tranche**”) (being the subject of Resolutions #2 to #5, inclusive).

At the same time, the Corporation also announced a proposed CDI purchase offer to the holders of CDIs in Australia and New Zealand as at the applicable record date of June 18, 2014 at an issue price of \$0.45 per CDI (the “**CDI Purchase Plan**”). Under the CDI Purchase Plan, those CDI holders will be offered the opportunity to subscribe for additional CDIs up to a maximum amount of \$15,000 per CDI holder and an aggregate subscription amount by all holders under the CDI Purchase Plan of \$1,080,000 (the “**Maximum Subscription Level**”). It is proposed that where the Corporation receives subscriptions under the CDI Purchase Plan exceeding the Maximum Subscription Level, all subscribers under the CDI Purchase Plan will be scaled back on a pro rata basis having regard to the amount applied for by the relevant CDI holder. The CDI Purchase Plan does not require shareholder approval.

The Corporation has received commitments under the Second Tranche from:

- (a) Dussman Pty. Ltd. and related entities (the “**Dussman Group**”) (an entity associated with Mr. Damien Haakman) to contribute further capital of \$2,775,996 for 6,168,880 common shares in the capital of the Corporation;
- (b) Ms. Philippa Lewis (and/or associates and affiliates of hers) to contribute further capital of \$50,000 for 111,112 common shares in the capital of the Corporation;
- (c) Mr. Peter Cook (and/or associates and affiliates of his) to contribute further capital of \$50,000 for 111,112 common shares in the capital of the Corporation; and

- (d) Mr. Ari Bergman (and/or associates and affiliates of his) to contribute further capital of \$50,000 for 111,112 common shares in the capital of the Corporation,

all at the same issue price as offered under the First Tranche and the CDI Purchase Plan.

Prior to the issue of the First Tranche, the Second Tranche and any CDI's pursuant to the CDI Purchase Plan:

- (a) the Dussman Group controlled approximately 42.4% of the Corporation's current issued common shares. As the Dussman Group is associated with one of the Corporation's current board members (Mr. Damien Haakman), prior disinterested shareholder approval for the allotment of the Corporation's issued common shares to the Dussman Group is required under the ASX Listing Rules;
- (b) Ms. Philippa Lewis (and/or associates and affiliates of hers) controlled approximately 0.7% of the Corporation's current issued common shares. As Ms. Lewis is one of the Corporation's current board members, prior disinterested shareholder approval for the allotment of the Corporation's issued common shares to Ms. Lewis (and/or associates and affiliates of hers) is required under the ASX Listing Rules;
- (c) Mr. Peter Cook (and/or associates and affiliates of his) controlled approximately 0.2% of the Corporation's current issued common shares. As Mr. Cook is one of the Corporation's current board members, prior disinterested shareholder approval for the allotment of the Corporation's issued common shares to Mr. Cook (and/or associates and affiliates of his) is required under the ASX Listing Rules; and
- (d) Mr. Ari Bergman (and/or associates and affiliates of his) controlled approximately 1.2% of the Corporation's current issued common shares. As Mr. Bergman is one of the Corporation's current board members, prior disinterested shareholder approval for the allotment of the Corporation's issued common shares to Mr. Bergman (and/or associates and affiliates of his) is required under the ASX Listing Rules.

The matters to be considered by shareholders at the Meeting relate to:

- Resolution #1 – approval and ratification of the First Tranche; and
- Resolutions #2 to #5 – approval of the issue of shares under the Second Tranche to Dussman Group (being a group associated with a director of the Corporation, Mr. Damien Haakman); Ms. Philippa Lewis (and/or associates and affiliates of hers) being a director of the Corporation; Mr. Peter Cook (and/or associates and affiliates of his) being a director of the Corporation; and Mr. Ari Bergman (and/or associates and affiliates of his) being a director of the Corporation.

Further information necessary for shareholder approval of the resolutions is set forth below:

Resolution #1 - Approval and Ratification of the First Tranche

(a) ASX Listing Rule 7.4

Resolution #1 seeks approval and ratification by the shareholders for the private placement of the First Tranche that was announced on June 18, 2014 in Canada (June 19, 2014 in Australia) and which closed on June 23, 2014 (the "**First Tranche**") for the purposes of ASX Listing Rule 7.4. The CDIs which comprise the First Tranche are expected to be issued on June 30, 2014.

ASX Listing Rule 7.1 provides that, subject to certain exceptions, prior approval of shareholders is required for the issue of equity securities if the equity securities will, when aggregated with the equity securities issued by a company during the previous 12 months, exceed 15% of the number of equity securities on issue at the commencement of that 12 month period.

ASX Listing Rule 7.4 states that an issue by a company of equity securities made without prior approval under ASX Listing Rule 7.1 is treated as having been made with approval for the purpose of ASX Listing Rule 7.1 if the issue did not breach ASX Listing Rule 7.1 and the company shareholders subsequently approve it.

The issue of common shares to professional and sophisticated investors the subject of the First Tranche is within the Corporation's 15% placement limit under ASX Listing Rule 7.1 and prior shareholder approval is not required in relation to the issue. The purpose of seeking shareholder approval and ratification of the issue of 6,886,673 common shares in this Resolution #1 (the "**First Tranche Shares**") is to effectively reinstate the ability of the Corporation to issue that number of common shares (i.e. 6,886,673) under the ASX Listing Rules in the following 12 consecutive month period without shareholder approval.

(b) ASX Listing Rule 7.5 disclosure requirements

In accordance with the disclosure requirements of ASX Listing Rule 7.5, the following information must be provided to shareholders to enable them to consider and ratify the issue of the First Tranche Shares in Resolution #1:

- (i) the number of First Tranche Shares allotted is 6,886,673 which are expected to be issued on June 30, 2014;
- (ii) the First Tranche Shares were issued at \$0.45 per First Tranche Share;
- (iii) the First Tranche Shares will be allotted as fully paid and rank equally with all existing common shares on issue;
- (iv) the subscribers under the First Tranche were professional and sophisticated investors including those introduced by the brokers and corporate advisors to the issue (Bell Potter Securities Limited, Shaw Corporate Finance Limited and Integrated Equity Pty. Ltd.);
- (v) the subscribers under the First Tranche are not related parties of the Corporation; and
- (vi) a total of \$3,099,003 (less costs associated with the issue) is expected to be raised by the issue of the First Tranche Shares. Funds to be raised from the First Tranche will be used to: (i) accelerate the roll-out of the Corporation's current technologies in the US and European markets; (ii) accelerate SIM™ Generation 5 (cloud compatible) product and SIM™ Community Care (home-based) product; (iii) appoint distributors to roll-out SIM™

Generation 4 in Europe; (iv) acquire and develop complimentary intellectual property; and (v) for general working capital purposes.

If Resolution #1 is not passed, the First Tranche Shares will be counted towards the 15% limit under ASX Listing Rule 7.1 for a period of 12 months from the date of issue.

The proposed text of Resolution #1 is set out in the accompanying Notice.

Resolution #1 must be passed by a majority of the disinterested shareholders. Therefore, the Corporation will disregard any votes cast on Resolution #1 by:

- (i) any investor who subscribed for First Tranche Shares; and
- (ii) an associate of any person (or persons) who subscribed for First Tranche Shares.

However, the Corporation need not disregard a vote if:

- (i) it is cast by a person as a proxy for a person who is entitled to vote, in accordance with the direction on the form of proxy; or
- (ii) it is cast by the person chairing the Meeting as proxy for a person who is entitled to vote, in accordance with a direction on the proxy form to vote as the proxy decides.

The directors of the Corporation unanimously recommend shareholders vote in favour of Resolution #1.

Background to Resolutions #2 to #5 – Approval and Authorization of the issue of common share to the Dussman Entities and to the Directors of Simavita and/or their associate and affiliates

ASX Listing Rule 10.11

As referred to above, the Corporation seeks approval from shareholders pursuant to Resolutions #2 to #5 (inclusive) to place 6,168,880 common shares of the Corporation at an issue price of \$0.45 per common share to the Dussman Entities, which are entities associated with one of the Corporation's directors (Mr. Damien Haakman); to place 111,112 common shares in the capital of the Corporation to a director of the Corporation Ms. Philippa Lewis (and/or associates and affiliates of hers); to place 111,112 common shares in the capital of the Corporation to a director of the Corporation Mr. Peter Cook (and/or associates and affiliates of his) and to place 111,112 common shares in the capital of the Corporation to a director of the Corporation Mr. Ari Bergman (and/or associates and affiliates of his), all of which placements being at an issue price of \$0.45 per common share.

ASX Listing Rule 10.11 prohibits the issue of any securities by the Corporation to a director or their associates unless either exempt under ASX Listing Rule 10.12 or prior shareholder approval is obtained (in accordance with ASX Listing Rule 10.13). Accordingly, the Corporation under Resolutions #2 to #5 (inclusive) is seeking separate shareholder approval and authorization for the respective allotments to each of the Dussman Entities; Ms. Philippa Lewis (and/or associates and affiliates of hers); Mr. Peter Cook (and/or associates and affiliates of his) and Mr. Ari Bergman (and/or associates and affiliates of his).

Resolution #2 - Approval and Authorization of the issue of common share to the Dussman Entities

As indicated above, in order for the Company to seek shareholder approval pursuant to ASX Listing Rule 10.11, it must provide the below information in accordance with ASX Listing Rule 10.13.

ASX Listing Rule 10.13 disclosure requirements

In accordance with the requirements of ASX Listing Rule 10.13, the following information is provided to shareholders to enable them to consider and approval Resolution #2:

- (i) it is proposed subject to shareholder approval that the Corporation issue common shares to the Dussman Entities;
- (ii) the number of common shares to be issued to the Dussman Entities is 6,168,880 common shares;
- (iii) it is proposed that the common shares will be issued no later than one month after the date of shareholder approval;
- (iv) the issue price is \$0.45 per common share; and
- (v) funds raised will be used to: (i) accelerate the roll-out of the Corporation's current technologies in the US and European markets; (ii) accelerate SIM™ Generation 5 (cloud compatible) product and SIM™ Community Care (home-based) product; (iii) appoint distributors to roll-out SIM™ Generation 4 in Europe; (iv) acquire and develop complimentary intellectual property; and (v) for general working capital purposes.

The proposed text of Resolution #2 is set out in the accompanying Notice.

Pursuant to ASX Listing Rule 7.2 Exception 14, if shareholders approve Resolution #2 pursuant to ASX Listing Rule 10.11, approval for Resolution #2 is not required pursuant to ASX Listing Rule 7.1.

Resolution #2 must be passed by a majority of the disinterested shareholders. Therefore, the Corporation will disregard any votes cast on Resolution #2 by:

- (i) a person who is to receive the securities the subject of this Resolution #2 (including, Dussman Pty. Ltd. and Mr. Damien Haakman); and
- (ii) an associate of any of the above persons.

However, the Corporation need not disregard a vote if:

- (i) it is cast by a person as a proxy for a person who is entitled to vote, in accordance with the direction on the form of proxy; or
- (ii) it is cast by the person chairing the Meeting as proxy for a person who is entitled to vote, in accordance with a direction on the proxy form to vote as the proxy decides.

The directors of the Corporation (absent Mr. Damien Haakman who declared his conflict of interest) unanimously recommend that shareholders vote in favour of Resolution #2.

Resolution #3 - Approval and Authorization of the issue of common share to Ms. Philippa Lewis

As indicated above, in order for the Company to seek shareholder approval pursuant to ASX Listing Rule 10.11, it must provide the below information in accordance with ASX Listing Rule 10.13.

ASX Listing Rule 10.13 disclosure requirements

In accordance with the requirements of ASX Listing Rule 10.13, the following information is provided to shareholders to enable them to consider and approval Resolution #3:

- (i) it is proposed subject to shareholder approval that the Corporation issue common shares to Ms. Philippa Lewis (and/or associates and affiliates of hers);
- (ii) the number of common shares to be issued to Ms. Philippa Lewis (and/or associates and affiliates of hers) is 111,112 common shares;
- (iii) it is proposed that the common shares will be issued no later than one month after the date of shareholder approval;
- (iv) the issue price is \$0.45 per common share; and
- (v) funds raised will be used to: (i) accelerate the roll-out of the Corporation's current technologies in the US and European markets; (ii) accelerate SIM™ Generation 5 (cloud compatible) product and SIM™ Community Care (home-based) product; (iii) appoint distributors to roll-out SIM™ Generation 4 in Europe; (iv) acquire and develop complimentary intellectual property; and (v) for general working capital purposes.

The proposed text of Resolution #3 is set out in the accompanying Notice.

Pursuant to ASX Listing Rule 7.2 Exception 14, if shareholders approve Resolution #3 pursuant to ASX Listing Rule 10.11, approval for Resolution #3 is not required pursuant to ASX Listing Rule 7.1.

Resolution #3 must be passed by a majority of the disinterested shareholders. Therefore, the Corporation will disregard any votes cast on Resolution #3 by:

- (i) a person who is to receive the securities the subject of this Resolution #3 (including, Ms. Philippa Lewis); and
- (ii) an associate of any of the above persons.

However, the Corporation need not disregard a vote if:

- (i) it is cast by a person as a proxy for a person who is entitled to vote, in accordance with the direction on the form of proxy; or
- (ii) it is cast by the person chairing the Meeting as proxy for a person who is entitled to vote, in accordance with a direction on the proxy form to vote as the proxy decides.

The directors of the Corporation (absent Ms. Philippa Lewis who declared her conflict of interest) unanimously recommend that shareholders vote in favour of Resolution #3.

Resolution #4 - Approval and Authorization of the issue of common share to Mr. Peter Cook

As indicated above, in order for the Company to seek shareholder approval pursuant to ASX Listing Rule 10.11, it must provide the below information in accordance with ASX Listing Rule 10.13.

ASX Listing Rule 10.13 disclosure requirements

In accordance with the requirements of ASX Listing Rule 10.13, the following information is provided to shareholders to enable them to consider and approval Resolution #4:

- (i) it is proposed subject to shareholder approval that the Corporation issue common shares to Mr. Peter Cook (and/or associates and affiliates of his);
- (ii) the number of common shares to be issued to Mr. Peter Cook (and/or associates and affiliates of his) is 111,112 common shares;
- (iii) it is proposed that the common shares will be issued no later than one month after the date of shareholder approval;
- (iv) the issue price is \$0.45 per common share; and
- (v) funds raised will be used to: (i) accelerate the roll-out of the Corporation's current technologies in the US and European markets; (ii) accelerate SIM™ Generation 5 (cloud compatible) product and SIM™ Community Care (home-based) product; (iii) appoint distributors to roll-out SIM™ Generation 4 in Europe; (iv) acquire and develop complimentary intellectual property; and (v) for general working capital purposes.

The proposed text of Resolution #4 is set out in the accompanying Notice.

Pursuant to ASX Listing Rule 7.2 Exception 14, if shareholders approve Resolution #4 pursuant to ASX Listing Rule 10.11, approval for Resolution #4 is not required pursuant to ASX Listing Rule 7.1.

Resolution #4 must be passed by a majority of the disinterested shareholders. Therefore, the Corporation will disregard any votes cast on Resolution #4 by:

- (i) a person who is to receive the securities the subject of this Resolution #4 (including, Mr. Peter Cook) and
- (ii) an associate of any of the above persons.

However, the Corporation need not disregard a vote if:

- (i) it is cast by a person as a proxy for a person who is entitled to vote, in accordance with the direction on the form of proxy; or
- (ii) it is cast by the person chairing the Meeting as proxy for a person who is entitled to vote, in accordance with a direction on the proxy form to vote as the proxy decides.

The directors of the Corporation (absent Mr. Peter Cook who declared his conflict of interest) unanimously recommend that shareholders vote in favour of Resolution #4.

Resolution #5 - Approval and Authorization of the issue of common share to Mr. Ari Bergman

As indicated above, in order for the Company to seek shareholder approval pursuant to ASX Listing Rule 10.11, it must provide the below information in accordance with ASX Listing Rule 10.13.

ASX Listing Rule 10.13 disclosure requirements

In accordance with the requirements of ASX Listing Rule 10.13, the following information is provided to shareholders to enable them to consider and approval Resolution #5:

- (i) it is proposed subject to shareholder approval that the Corporation issue common shares to Mr. Ari Bergman (and/or associates and affiliates of his);
- (ii) the number of common shares to be issued to Mr. Ari Bergman (and/or associates and affiliates of his) is 111,112 common shares;
- (iii) it is proposed that the common shares will be issued no later than one month after the date of shareholder approval;
- (iv) the issue price is \$0.45 per common share; and
- (v) funds raised will be used to: (i) accelerate the roll-out of the Corporation's current technologies in the US and European markets; (ii) accelerate SIM™ Generation 5 (cloud compatible) product and SIM™ Community Care (home-based) product; (iii) appoint distributors to roll-out SIM™ Generation 4 in Europe; (iv) acquire and develop complimentary intellectual property; and (v) for general working capital purposes.

The proposed text of Resolution #5 is set out in the accompanying Notice.

Pursuant to ASX Listing Rule 7.2 Exception 14, if shareholders approve Resolution #5 pursuant to ASX Listing Rule 10.11, approval for Resolution #5 is not required pursuant to ASX Listing Rule 7.1.

Resolution #5 must be passed by a majority of the disinterested shareholders. Therefore, the Corporation will disregard any votes cast on Resolution #5 by:

- (i) a person who is to receive the securities the subject of this Resolution #5 (including, Mr. Ari Bergman); and
- (ii) an associate of any of the above persons.

However, the Corporation need not disregard a vote if:

- (i) it is cast by a person as a proxy for a person who is entitled to vote, in accordance with the direction on the form of proxy; or
- (ii) it is cast by the person chairing the Meeting as proxy for a person who is entitled to vote, in accordance with a direction on the proxy form to vote as the proxy decides.

The directors of the Corporation (absent Mr. Ari Bergman who declared his conflict of interest) unanimously recommend that shareholders vote in favour of Resolution #5.

AUDITORS OF THE CORPORATION

On May 2, 2014, the Board of Directors of the Corporation removed De Visser Gray LLP as the auditor of the Corporation and appointed PricewaterhouseCoopers LLP as the new auditors effective May 2, 2014. In connection with this previous change in auditor, the complete change of auditor reporting package was filed on SEDAR at www.sedar.com and is attached as Schedule “A” to this Circular.

INDEBTEDNESS OF DIRECTORS, EXECUTIVE OFFICERS AND EMPLOYEES

No individual who is, or at any time during the Corporation’s most recently completed financial year was, a director or executive officer of the Corporation, and no associate of any such director, executive officer is, or at any time during the Corporation’s most recently completed financial year was, indebted to (i) the Corporation or any of its subsidiaries or (ii) indebted to another entity where such indebtedness is or has been the subject of a guarantee, support agreement, letter of credit or other similar arrangement or understanding provided by the Corporation or any of its subsidiaries, other than routine indebtedness.

MANAGEMENT CONTRACTS

There are no management functions of the Corporation or any of its subsidiaries which are to any substantial degree performed by a person other than the directors or executive officers of the Corporation or subsidiary.

INTEREST OF CERTAIN PERSONS IN MATTERS TO BE ACTED UPON

None of the directors or executive officers of the Corporation, none of the persons who have been directors or executive officers of the Corporation since the commencement of the Corporation’s last completed financial year, and no associate or affiliate of any of the foregoing has any material interest, direct or indirect, by way of beneficial ownership of securities or otherwise, in any matter to be acted upon at the Meeting.

INTEREST OF INFORMED PERSONS IN MATERIAL TRANSACTIONS

Other than as disclosed elsewhere in this Information Circular, there were no material interests, direct or indirect, of any informed person of the Corporation, any director of the Corporation, or any known associates or affiliates of any informed person or director, in any transaction since the commencement of the Corporation’s most recently completed financial year or in any proposed transaction which has materially affected or would materially affect the Corporation or any of its subsidiaries.

ADDITIONAL INFORMATION

Additional information relating to the Corporation can be obtained on the Canadian Securities Administrators’ System for Electronic Document Analysis and Retrieval (SEDAR) at www.sedar.com.

Financial information is provided in the Corporation’s comparative financial statements and management’s discussion and analysis for the Corporation’s most recently completed financial year. Copies of the Corporation’s financial statements and management’s discussion and analysis are available upon request from Tom Howitt, the Corporation’s Chief Financial Officer at thowitt@simavita.com.

APPROVAL

The contents of this Information Circular and the sending thereof have been approved by the Board.

DATED the 25th day of June, 2014.

“Philippa Lewis”

Philippa M. Lewis

Chief Executive Officer and Executive Director

Schedule "A"
Notice of Change of Auditor



Level 12, 56 Berry Street
North Sydney NSW 2060
Tel +61 2 8405 6300
Fax +61 2 8088 1301
www.simavita.com

Simavita Limited
Change of Auditor Notice
Pursuant to National Instrument 51-102, Section 4.11

I. Former auditor

- a. On 2 May 2014, Simavita Limited removed De Visser Gray LLP as its auditor during its current term of appointment.
- b. The Audit Committee (and the Board of Directors) participated in and approved the decision to change the auditor.
- c. The auditor's reports of De Visser Gray LLP on the financial statements of Simavita Limited for the two years ended 30 April 2012 and 30 April 2013, respectively, did not contain any modifications as to departures from generally accepted accounting principles or limitation in the scope of the audit.
- d. In connection with the audits for the two years ended 30 April 2012 and 30 April 2013, respectively, and through to 2 May 2014, there have been no reportable events, as defined in the National Instrument.

II. Successor auditor

The Company appointed PricewaterhouseCoopers as its new auditor as of 2 May 2014. The Audit Committee and the Board of Directors considered and approved the appointment.

Dated at Sydney, New South Wales, Australia this 8th day of May, 2014.

THOMAS G. HOWITT
Company Secretary

Letter from Former Auditor

DeVISSER GRAY LLP
CHARTERED ACCOUNTANTS

401-905 West Pender St
Vancouver BC V6C 1L6
t 604.687.5447
f 604.687.6737

May 12, 2014

BC Securities Commission
Alberta Securities Commission
Yukon Securities Commission

Dear Sirs/Mesdames:

Change of Auditor of Simavita Limited (the "Company")

We acknowledge receipt of a Notice of Change of Auditor (the "Notice") dated May 2, 2014 given by the Company to ourselves.

Based on our information as of this date, we agree with the statements set out in the Notice.

Yours truly,



DeVisser Gray LLP

Per: G. Cameron Dong Ltd.

Letter from Successor Auditor



13 May 2014

BC Securities Commission
Alberta Securities Commission
Yukon Securities Commission

Dear Sirs/Mesdames:

We have read the statements made by Simavita Limited in the attached copy of change of auditor notice dated 8 May 2014, which we understand will be filed pursuant to Section 4.11 of National Instrument 51-102.

We agree with the statements in the change of auditor notice dated 8 May 2014.

Yours very truly,

A handwritten signature in black ink, appearing to read "PricewaterhouseCoopers", written over a horizontal line.

PricewaterhouseCoopers


By

A handwritten signature in black ink, appearing to read "Sam Loble", written over a horizontal line.

Sam Loble
Partner

PricewaterhouseCoopers, ABN 52 780 433 757
Freshwater Place, 2 Southbank Boulevard, SOUTHBANK VIC 3006, GPO Box 1331, MELBOURNE VIC 3001
T: 61 3 8603 1000, F: 61 3 8603 1999, www.pwc.com.au

Liability limited by a scheme approved under Professional Standards Legislation.



Simavita
gracing life

ARBN 165 831 309

└ 000001 000 SVA
MR SAM SAMPLE
FLAT 123
123 SAMPLE STREET
THE SAMPLE HILL
SAMPLE ESTATE
SAMPLEVILLE VIC 3030

Lodge your vote:



By Mail:

Computershare Investor Services Pty Limited
GPO Box 242 Melbourne
Victoria 3001 Australia

Alternatively you can fax your form to
(within Australia) 1800 783 447
(outside Australia) +61 3 9473 2555

For all enquiries call:

(within Australia) 1300 850 505
(outside Australia) +61 3 9415 4000

CDI Voting Instruction Form



**For your vote to be effective it must be received by
10:00am (AEST) Sunday 20 July 2014**

How to Vote on Items of Business

Each CHESS Depositary Interest (CDI) is equivalent to one share of Company Common Stock, so that every 1 (one) CDI registered in your name at 12 June 2014 entitles you to one vote.

You can vote by completing, signing and returning your CDI Voting Instruction Form. This form gives your voting instructions to CHESS Depositary Nominees Pty Ltd, which will vote the underlying shares on your behalf. You need to return the form no later than the time and date shown above to give CHESS Depositary Nominees Pty Ltd enough time to tabulate all CHESS Depositary Interest votes and to vote on the underlying shares.

Signing Instructions

Individual: Where the holding is in one name, the securityholder must sign.

Joint Holding: Where the holding is in more than one name, all of the securityholders should sign.

Power of Attorney: If you have not already lodged the Power of Attorney with the Australian registry, please attach a certified photocopy of the Power of Attorney to this form when you return it.

Companies: Only duly authorised officer/s can sign on behalf of a company. Please sign in the boxes provided, which state the office held by the signatory, ie Sole Director, Sole Company Secretary or Director and Company Secretary. Delete titles as applicable.

Comments & Questions: If you have any comments or questions for the company, please write them on a separate sheet of paper and return with this form.

Turn over to complete the form →



View your securityholder information, 24 hours a day, 7 days a week:

www.investorcentre.com

- ☒ **Review your securityholding**
- ☒ **Update your securityholding**

Your secure access information is:

SRN/HIN: I9999999999



PLEASE NOTE: For security reasons it is important that you keep your SRN/HIN confidential.

MR SAM SAMPLE
FLAT 123
123 SAMPLE STREET
THE SAMPLE HILL
SAMPLE ESTATE
SAMPLEVILLE VIC 3030



Change of address. If incorrect, mark this box and make the correction in the space to the left. Securityholders sponsored by a broker (reference number commences with 'X') should advise your broker of any changes.



I 9999999999

I ND

CDI Voting Instruction Form

Please mark ☒ to indicate your directions

STEP 1 CHESS Depositary Nominees Pty Ltd will vote as directed

XX

Voting Instructions to CHESS Depositary Nominees Pty Ltd

I/We being a holder of CHESS Depositary Interests of Simavita Limited hereby direct CHESS Depositary Nominees Pty Ltd to vote the shares underlying my/our holding at the Special Meeting of Shareholders of Simavita Limited to be held at Level 13, 54 Miller Street, North Sydney NSW 2060 on Wednesday 23 July 2014 at 10:00 am (AEST) and at any adjournment or postponement of that meeting.

By execution of this CDI Voting Form the undersigned hereby authorises CHESS Depositary Nominees Pty Ltd to appoint such proxies or their substitutes to vote in their discretion on such business as may properly come before the meeting.

STEP 2 Items of Business

ORDINARY BUSINESS

	For	Against
Item 1 First Tranche Issuance	<input type="checkbox"/>	<input type="checkbox"/>
Item 2 Insider Participation	<input type="checkbox"/>	<input type="checkbox"/>
Item 3 Participation of Ms. Philippa Lewis, a Director of Simavita Limited	<input type="checkbox"/>	<input type="checkbox"/>
Item 4 Participation of Mr. Peter Cook, a Director of Simavita Limited	<input type="checkbox"/>	<input type="checkbox"/>
Item 5 Participation of Mr. Ari Bergman, a Director of Simavita Limited	<input type="checkbox"/>	<input type="checkbox"/>

Important Note: If the proxyholder so appointed is the Chair of the Meeting, and if the holder has not specified a choice with respect to Item #3, any votes cast by the Chair other than as proxyholder will be disregarded because of the Chair's interest in Item #3.

SIGN Signature of Securityholder(s) *This section must be completed.*

Individual or Securityholder 1

Sole Director and Sole Company Secretary

Securityholder 2

Director

Securityholder 3

Director/Company Secretary

Contact
Name

Contact
Daytime
Telephone

Date / /

SVA

1 8 5 4 8 0 A

Computershare +



8th Floor, 100 University Avenue
Toronto, Ontario M5J 2Y1
www.computershare.com

GNSQ 000001

SAM SAMPLE
123 SAMPLES STREET
SAMPLETOWN SS X9X X9X
CANADA

Security Class COMMON SHARES

Holder Account Number
C9999999999 I ND



Fold

Form of Proxy - Special Meeting to be held on Wednesday, July 23, 2014 (Australia)

This Form of Proxy is solicited by and on behalf of Management.

Notes to proxy

1. Every holder has the right to appoint some other person or company of their choice, who need not be a holder, to attend and act on their behalf at the meeting or any adjournment or postponement thereof. If you wish to appoint a person or company other than the persons whose names are printed herein, please insert the name of your chosen proxyholder in the space provided (see reverse).
2. If the securities are registered in the name of more than one owner (for example, joint ownership, trustees, executors, etc.), then all those registered should sign this proxy. If you are voting on behalf of a corporation or another individual you must sign this proxy with signing capacity stated, and you may be required to provide documentation evidencing your power to sign this proxy.
3. This proxy should be signed in the exact manner as the name(s) appear(s) on the proxy.
4. If this proxy is not dated, it will be deemed to bear the date on which it is mailed by Management to the holder.
5. **The securities represented by this proxy will be voted as directed by the holder, however, if such a direction is not made in respect of any matter, this proxy will be voted as recommended by Management.**
6. The securities represented by this proxy will be voted in favour or withheld from voting or voted against each of the matters described herein, as applicable, in accordance with the instructions of the holder, on any ballot that may be called for and, if the holder has specified a choice with respect to any matter to be acted on, the securities will be voted accordingly.
7. If the proxyholder so appointed is the Chair of the Meeting, and if the holder has not specified a choice with respect to Resolution #3, any votes cast by the Chair other than as proxyholder will be disregarded because of the Chair's interest in Resolution #3.
8. This proxy confers discretionary authority in respect of amendments or variations to matters identified in the Notice of Meeting or other matters that may properly come before the meeting or any adjournment or postponement thereof.
9. This proxy should be read in conjunction with the accompanying documentation provided by Management.

Fold

Proxies submitted must be received by 10:00 AM, Australian Eastern Standard Time, on Monday, July 21, 2014.



Appointment of Proxyholder

I/We, being holder(s) of Simavita Limited hereby appoint: Philippa Lewis, Chief Executive Officer and Executive Director of Simavita Limited, or failing her, Thomas Howitt, Chief Financial Officer of Simavita Limited,

OR

Print the name of the person you are appointing if this person is someone other than the Chairman of the Meeting.

as my/our proxyholder with full power of substitution and to attend, act and to vote for and on behalf of the shareholder in accordance with the following direction (or if no directions have been given, as the proxyholder sees fit) and all other matters that may properly come before the Special Meeting of shareholders of Simavita Limited to be held at the offices of the Company, Level 13, 54 Miller Street, North Sydney, NSW 2060, Australia, on Wednesday, July 23, 2014 at 10:00 AM (Australian Eastern Standard Time) and at any adjournment or postponement thereof.

VOTING RECOMMENDATIONS ARE INDICATED BY **HIGHLIGHTED TEXT** OVER THE BOXES.

	For	Against
1. First Tranche Issuance Approving and ratifying, for the purposes of ASX Listing Rule 7.4 and all other purposes, the prior issue to professional and sophisticated investors of 6,886,673 common shares in the capital of Simavita Limited at an issue price of AUD \$0.45 per share, and otherwise as more particularly described in the Management Information Circular.	<input type="checkbox"/>	<input type="checkbox"/>
2. Insider Participation Approving and authorizing, for purposes of ASX Listing Rule 10.11 and all other purposes, the issue to an insider, Dussman Pty. Ltd. (an entity associated with Director, Damien Haakman), of 6,168,800 common shares in the capital of the Corporation at an issue price of AUD \$0.45 per share, and otherwise as more particularly described in the Management Information Circular.	<input type="checkbox"/>	<input type="checkbox"/>
3. Participation of Ms. Philippa Lewis, a Director of Simavita Limited Approving and authorizing, for the purposes of the ASX Listing Rule 10.11 and all other purposes, the issue to Ms. Philippa Lewis (and/or associates and affiliates of hers) of 111,112 common shares in the capital of Simavita Limited at an issue price of AUD\$0.45 per share, and otherwise as more particularly described in the accompanying Management Information Circular.	<input type="checkbox"/>	<input type="checkbox"/>
4. Participation of Mr. Peter Cook, a Director of Simavita Limited Approving and authorizing, for the purposes of the ASX Listing Rule 10.11 and all other purposes, the issue to Mr. Peter Cook (and/or associates and affiliates of his) of 111,112 common shares in the capital of Simavita Limited at an issue price of AUD\$0.45 per share, and otherwise as more particularly described in the accompanying Management Information Circular.	<input type="checkbox"/>	<input type="checkbox"/>
5. Participation of Mr. Ari Bergman, a Director of Simavita Limited Approving and authorizing, for the purposes of the ASX Listing Rule 10.11 and all other purposes, the issue to Mr. Ari Bergman (and/or associates and affiliates of his) of 111,112 common shares in the capital of Simavita Limited at an issue price of AUD\$0.45 per share, and otherwise as more particularly described in the accompanying Management Information Circular.	<input type="checkbox"/>	<input type="checkbox"/>

Authorized Signature(s) - This section must be completed for your instructions to be executed.

I/We authorize you to act in accordance with my/our instructions set out above. I/We hereby revoke any proxy previously given with respect to the Meeting. If no voting instructions are indicated above, this Proxy will be voted as recommended by Management.

Signature(s)

Date

DD / MM / YY



Share Purchase Plan

OFFER DOCUMENT

This non-renounceable offer (Offer) of new fully paid CHESS Depository Interests (CDIs) (New CDIs) each CDI representing an interest in one share in the capital of Simavita Limited ARBN 165 831 309 (Company) is made on the terms and conditions of the Share Purchase Plan (Plan) set out in this Offer Document and the accompanying Application Form.

It is important to ensure that you read this Offer Document and accompanying Application Form in full. You should seek independent legal and/or financial advice if you are in any doubt about the terms of this offer or whether to accept this offer.

Simavita Share Purchase Plan Offer

KEY OFFER DETAILS

Issue Price	45 cents (\$0.45) per New CDI
Minimum application amount	\$1,000 per shareholder
Maximum application amount	\$15,000 per shareholder
Applications can be made for parcels of CDIs (rounded to the next whole number of CDIs) valued at:*	A \$1,000 (2,222 New CDIs) B \$2,000 (4,444 New CDIs) C \$4,000 (8,889 New CDIs) D \$7,500 (16,667 New CDIs) E \$10,000 (22,222 New CDIs) F \$15,000 (33,333 New CDIs)
Maximum amount to be raised^	\$1,080,000
Proposed use of funds	Funds raised from this offer will be principally used to accelerate the Company's roll-out of its SIMT TM products in the US market
Record Date (for determining recipients of the Offer)+	7.00pm Melbourne time on Wednesday, 18 June 2014, being the last trading day before the date on which the details of the Plan were first announced to the ASX
Closing Date+	Friday, 25 July 2014
Anticipated date of issue of New CDIs+	Wednesday, 30 July 2014
Anticipated dispatch of holding statements and (if applicable) refunds+	Thursday, 31 July 2014
Anticipated commencement of trading of New CDIs+	Monday, 4 August 2014

* Custodians may apply for up to \$15,000 on behalf of each distinct beneficiary represented, using a separate Application Form for each beneficiary, which Application Form can be obtained from the Company or its Share Registrar or downloaded from its website: www.simavita.com. Further details are provided below.

^If the total number of New CDIs applied for exceeds \$1,080,000, the Company will reduce the number of CDIs to be issued in response to each application on a pro rata basis. In that case, the Company will refund to each applicant the difference between the application monies received by the Company from that applicant and application monies payable for the number of New CDIs actually issued to that applicant. Refunds will be paid to the applicant by cheque. No interest shall be paid on refunded application monies.

+ The above dates are indicative only. The Company reserves the right to change any date without notice, including by postponing the closing date or closing the Offer early, or to withdraw or cancel the Offer (in which case all monies subscribed will be refunded).

If you wish to participate in this Plan you must apply for New CDIs using the personalised Application Form accompanying this Offer Document, unless you are a custodian and wish to apply on behalf of distinct beneficiaries. If any of your details on the Application Form are incorrect, please contact the Company's Share Registrar urgently.

Terms and Conditions of Plan Offer

1. Participation

Participation in the Plan is open on the same terms to all shareholders (Eligible Members) who, as at the record date of Wednesday, 18 June 2014, are registered holders of CDIs in Simavita Limited and who have an address (as recorded in the Company's register of members) in Australia or New Zealand by subscribing for up to \$15,000 of new fully paid CDIs (New CDIs) in the Company without incurring brokerage, commission, stamp duty or other transaction costs.

The Plan is established pursuant to Australian Securities and Investments Commission (ASIC) Regulatory Guide 125, Class Order 09/425 and the ASX Listing Rules. That Class Order grants the Company relief from the requirement to prepare a prospectus for the offer of New CDIs under the Plan.

Participation in the Plan is optional and by accepting the offer to purchase New CDIs under the Plan, each holder agrees to be bound by the terms and conditions of the Offer and the Company's constitution.

The maximum aggregate number of CDIs that may be issued under the Plan will be 2,400,000, being approximately 3.92 percent of the Company's fully paid CDIs currently on issue as at the date of this Offer.

The Company also reserves the right (in its absolute discretion) to scale back applications should aggregate demand exceed \$1,080,000. Excess subscription monies will be refunded (without interest) as soon as reasonably practicable.

The Plan is governed by the law in force in Victoria. By accepting the offer under the Plan, a holder submits to the non-exclusive jurisdiction of the courts of Victoria.

All references to \$ amounts in the Plan and this Offer document are to Australian dollars.

2. Issue price

The CDIs are being offered at an issue price of \$0.45 (45 cents) per CDI.

The Issue Price represents a 8.1% discount to the last close price on ASX (\$0.49) prior to the trading halt on Thursday, 19 June 2014 (AEST), and a 15.1% discount to the Volume Weighted Average Price ("VWAP") for the five trading days prior to that date (\$0.53).

No brokerage, commissions, stamp duty or other transaction costs will be payable in respect of the application for and issue of the New CDIs under the Plan.

As the Company's CDI price may increase or decrease between the date the Offer is made under the Plan and the date when the New CDIs are allotted and issued to Eligible Members under the Plan, the price paid by a member for the New CDIs under the Plan may be higher or lower than the CDI price at the time of the Offer or at the time the New CDIs are issued and allotted to the eligible Member.

The minimum value of New CDIs for which each Eligible Member may subscribe under this Offer is \$1,000 and the maximum value of New CDIs for which each Eligible Member may subscribe is \$15,000 (subject to scale back described further below). The following rules apply to participation by Eligible Members:

3. Eligibility for participation

Offers made under the Plan are non-renounceable. This means that a holder cannot transfer their right to acquire New CDIs under the Plan to anyone else. New CDIs subscribed for will be issued only to the registered holder to whom they are offered. Each Offer is made on the same terms and conditions. All eligible holders receive the same offer, irrespective of the number of CDIs which they hold on the Record Date.

Directors and officers of the Company (and their associates) who hold CDIs as at the Record Date may participate in the offer, subject to the terms and conditions set out in this Offer Document and Application Form.

3.1 Individual members

Unless a holder is a Custodian (defined below), each individual member is entitled to apply for up to a maximum amount of \$15,000 New CDIs (irrespective of whether the individual member receives multiple offers under the Plan, for example, due to multiple registered holdings), subject to the individual member certifying that the total of the application moneys subscribed for the following does not exceed \$15,000:

- a) the New CDIs the subject of the Acceptance Form (pursuant to this Plan); and
- b) any other fully paid CDIs in Simavita Limited:
 - i) issued to that sole holder; and
 - ii) which that sole holder has instructed a custodian to acquire on their behalf; and
 - iii) issued to a custodian as a result of an instruction given by that sole holder to the custodian to apply for shares on their behalf,under the Plan or any similar arrangement in the 12 months before the application (but noting that Simavita Limited has not conducted a share purchase plan or similar Plan in the prior 12 months).

By completing and submitting (or by making payment via BPAY) the personalised offer and Acceptance Form (referred to below) which accompanies the Plan, a sole holder certifies the above statements in clause 3.1.

3.2 Joint Holders

Unless a holder is a Custodian (defined below), if a holder is recorded with one or more other persons as the joint holder of the Company's CDIs, the joint holding is considered a single registered holding for the purpose of the Plan. Joint holders are entitled to participate in respect of that single holding and may apply for up to a maximum amount of \$15,000 New CDIs (irrespective of whether the holder and the other person or persons receive multiple offers under the Plan, for example, due to multiple identical registered holdings), subject to the joint holder certifying that the total of the application moneys subscribed for the following does not exceed \$15,000:

- a) the New CDIs the subject of the Acceptance Form (pursuant to this Plan) returned; and
- b) any other fully paid CDIs in the Company:
 - i) issued to that joint holder; and
 - ii) which that joint holder has instructed a custodian to acquire on their behalf; and
 - iii) issued to a custodian as a result of an instruction given by that joint holder to the custodian to apply for CDIs on their behalf,under the Plan or any similar arrangement in the 12 months before the application.

By completing and submitting (or by making payment via BPAY) the personalised offer and Acceptance Form (referred to below) which accompanies the Plan, a joint holder certifies the above statements in clause 3.2.

3.3 Custodians and Nominees

Eligible Members who hold CDIs as custodian or nominee as defined in ASIC class order CO 09/425 (“Custodian”) for one or more persons on the Record Date (“Beneficiaries”) may apply for up to a maximum amount of \$15,000 New CDIs in respect of each Beneficiary subject to the Custodian:

- a) certifying to the Company that the Custodian is an eligible holder of CDIs in the Company on behalf of one or more Beneficiaries, a copy of the Offer documentation was given by the Custodian to each Beneficiary and each Beneficiary requiring New CDIs has instructed the Custodian to apply for the New CDIs on its behalf under the Plan and in addition the Custodian provides the following details:
 - i) the number of Beneficiaries instructing the Custodian to participate;
 - ii) the name and address of each participating Beneficiary; and
 - iii) in respect of each participating Beneficiary:
 - the number of fully paid ordinary CDIs in the Company that the Custodian holds on their behalf; and
 - the number or the dollar amount of New CDIs they instructed the Custodian to apply for on their behalf; and
 - undertaking not to, in respect of the Plan or other similar plan, accept on behalf of any Beneficiary, in any consecutive 12 month period, CDIs in the Company with an aggregate application price which exceeds \$15,000.

By completing and submitting (or by making payment via BPAY) the personalised offer and Acceptance Form (referred to below) which accompanies this offer, a Custodian certifies the above statements in clause 3.3.

If a Custodian requires more than one personalised offer and Acceptance Form to provide the above information, the Custodian should contact the Company or the Company's share registrar and make that request.

* It is at the discretion of the Custodian whether to extend the Offer to all of their Beneficiaries.

4. How to apply for new CDIs

The Offer to participate in the Plan opens on Wednesday, 25 June 2014.

An offer to participate in the Plan may be accepted by a registered Eligible Member (Acceptance) by completing and returning the personalised offer and acceptance form (Acceptance Form) provided by the Company, together with the appropriate payment for the amount to which the acceptance relates (by cheque in Australian dollars drawn on an Australian bank made payable to “Simavita Limited SPP Account”), by no later than the Offer closing date, Friday, 25 July 2014 (Closing Date). Acceptances received after that time will not be accepted.

Acceptance includes making payment using the BPAY facility offered by Computershare Investor Services Pty Limited, but only via the customer reference number as described on your personalised Acceptance Form, by no later than the Closing Date (in which case the Acceptance Form need not be returned to the Company).

If Acceptance (via BPAY) or one or more Acceptance Forms are received from an Eligible Member in relation to CDIs with a value greater than \$15,000, the Eligible Member holder will be issued with the maximum number of New CDIs permitted by the Plan. The difference between the subscription moneys received from such member, and the number of New CDIs allocated to that member multiplied by the Issue Price, will be refunded to the eligible Member by cheque, without payment of any interest, as soon as reasonably practicable following allotment of all the New CDIs.

If an Eligible Member subscribes for an amount which is not exactly divisible by the Issue Price for the CDIs, in calculating the number of CDIs to be issued, all fractional entitlements will be rounded to the nearest whole CDI.

Notwithstanding any other provision in these terms and conditions, the Board may, in its sole discretion, reject any Acceptance Form which is received from ineligible members or otherwise which:

- a) is incomplete, incorrectly filled out or accompanied by a cheque which is not paid in full on first presentation; or
- b) the Board believes is completed by a person within, or a person acting for the account or benefit of a person within, another jurisdiction where, in the reasonable opinion of the Board, it would be unlawful or impractical for the Company to issue the New CDIs.

If a cheque is not cleared through the banking system, the member's Acceptance Form will not be accepted and the member will be deemed to agree to be responsible for any dishonour fees or other costs incurred. If a cheque is dishonoured, that dishonoured cheque will not be re-presented.

Once submitted, Applications for New CDIs under the Plan cannot be withdrawn or amended. Shareholders should consult their taxation or investment advisers to clarify the financial and taxation implications for them in subscribing for CDI under the Plan.

5. Scale back

The Company intends to raise \$1,080,000 via the Plan and reserves the right (in its absolute discretion) to scale back applications should total demand exceed that amount. Any scale back of applications will be done on a pro-rata basis for all applications received. Excess subscription monies will be refunded (without interest) as soon as reasonably practicable.

The difference between the subscription moneys received from each eligible Member, and the number of New CDIs allocated to each Eligible Member multiplied by the Issue Price, will be refunded to member by cheque, without payment of any interest, as soon as reasonably practicable.

6. Issue of new CDIs

The New CDIs to be issued pursuant to the Offer under the Plan will be issued as soon as reasonably practicable after the Closing Date and the Company will apply for those CDIs to be quoted on the ASX.

The Company will, within the period required by the ASX Listing Rules, send each participant (whose Acceptance Form has been accepted by the Company) a holding statement in respect of any New CDIs issued to the participant under the Plan.

CDIs issued under the Plan will rank equally with all existing CDIs in the Company and will therefore carry the same voting rights, dividend rights and other entitlements as those CDIs from the date of issue.

Unless permitted under relevant securities legislation, the New CDIs will not be tradable in Canada before any date that is four months and a day after the date of issue of the New CDIs.

7. Excluded applicants

A shareholder who alone or with its associates would obtain an interest in more than 20% of the issued voting CDIs of the Company may be ineligible to accept an offer under the Plan. The Company reserves the right to refuse an application if the applicant (alone or with its associates) would obtain an interest in more than 20% of the issued voting CDIs of the Company. In the event that an application is adjusted, the Company will refund to the applicant by cheque without interest the between the application monies received by the Company and application monies payable for the number of CDIs actually issued to the applicant.

8. No shareholder approval required

The Company is not required to seek the approval of Shareholders in relation to the offer of New CDIs under the Plan.

9. Amendment of the plan

The Board may, in its absolute discretion, amend, suspend or terminate the Plan at any time (including, without limitation, by extending the Closing Date). The Company will notify ASX of any amendment, suspension or termination of the Plan, but failure to do so will not invalidate the amendment, suspension or termination.

The Company may issue to any person fewer CDIs than subscribed for under the Plan (or none at all) if the Company believes that the issue of those CDIs would contravene any law or the ASX Listing Rules or the Corporations Act 2001.

10. Administration and dispute resolution

The Company's principal objective in administering the Plan is to facilitate maximum participation consistent with compliance with ASIC Class Order CO 09/425 and all applicable laws and efficient administrative practices.

The Company may adopt any administrative procedures it thinks appropriate (from time to time) in relation to the Plan. The Company may settle, in any manner it thinks fit, any difficulties, anomalies or disputes which may arise under or in connection with the operation of the Plan, whether generally or in relation to any participant or class of participants, the Offer, any Acceptance Form or New CDIs, and the decision of the Company will be conclusive and binding on all participants and other persons to whom the determination relates.

The Company reserves the right (subject to the Corporations Act 2001 and ASIC Class Order 09/425) to waive compliance with any provision of these terms and conditions.

11. Notices

Notices and statements to participating shareholders may be given in any manner determined by the Company.

12. Privacy act

Chapter 2C of the Corporations Act 2001 (Cth) (the Act) requires information about shareholders (including name, address and details of the CDIs held) to be included in the Company's public register. If a shareholder ceases to be a shareholder, Chapter 2C of the Act requires this information to be retained in the Company's public register. These statutory obligations are not altered by the Privacy Act 1988 (Cth) as amended. Information is collected to administer shareholders' security holdings.

13. No financial product advice

Shareholders should obtain their own advice on whether or not to participate in the Plan. The Company is not licensed to provide financial product advice in relation to the Company's CDIs or any other financial products. No cooling off regime applies in respect of the acquisition of CDIs under the Plan (whether the regime is provided for by law or otherwise).

14. Enquiries

If you have any question about the offer, or whether or not to accept the offer, please contact your stockbroker or professional adviser, or Mr. Tom Howitt, Company Secretary, on (02) 8405 6300 (within Australia) or +61 2 8405 6300 (outside Australia). If you have any questions on how to complete the Application Form please contact the Company's Share Registry on 1300 850 505 (within Australia) or +61 3 9415 4000 (outside Australia), between Monday to Friday 9.00am to 5.00pm.


For all enquiries:

Phone:
 (within Australia) + 61 2 8405 6300

Web:
 www.investorcentre.com

└ 000001 000 SVA
MR SAM SAMPLE
123 SAMPLE STREET
SAMPLETOWN VIC 3000

Make your payment:

 See overleaf for details of the Offer and how to make your payment

Share Purchase Plan Application Form

 **Your payment must be received by 5:00pm (AEST) Friday 25th July 2014**

This is an important document that requires your immediate attention.

It can only be used in relation to the shareholding represented by the details printed overleaf. If you are in doubt about how to deal with this form, please contact your financial or other professional adviser.

By making payment you agree to be bound by the Constitution of Simavita Limited (the Company) and that the submission of this payment constitutes an irrevocable offer by you to subscribe for the Company shares on the terms of the Share Purchase Plan (SPP). In addition, by submitting the payment slip below you certify that the aggregate of the application price paid by you for:

- the shares the subject of the payment slip below; and
- any other shares and interests in the class applied for by you under the SPP or any similar arrangement in the 12 months prior to the date of submission of the payment slip below does not exceed A\$15,000.

The Company may make determinations in any manner it thinks fit, in relation to any difficulties which may arise in connection with the SPP whether generally or in relation to any participant or application.

Any determinations by the Company will be conclusive and binding on all eligible shareholders and other persons to whom the determination relates. The Company reserves the right to waive strict compliance with any provision of the terms and conditions of the SPP, to amend or vary those terms and conditions or to suspend or terminate the SPP at any time. Any such amendment, suspension or termination will be binding on all eligible shareholders even where the Company does not notify you of that event.

Step 1: Registration Name

Please check the details provided and update your address via www.investorcentre.com if any of the details are incorrect.

If you have a CHESS sponsored holding, please contact your Controlling Participant to notify a change of address.

Step 2: Make Your Payment

Note that shares may be purchased subject to purchase of the minimum value and not exceeding the maximum value. Note that the amount chosen may be subject to scale back in accordance with the terms of the SPP.

Choose one of the payment methods shown below.

BPAY®: See overleaf. Do not return the payment slip with BPAY payment.

By Mail: Complete the reverse side of this payment slip and detach and return with your payment. Make your cheque, bank draft or money order payable in Australian dollars to **"Simavita Limited"** and crossed **"Not Negotiable"**. The cheque must be drawn from an Australian bank. Cash is not accepted.

Payment will be processed on the day of receipt. Receipts will not be forwarded. Funds cannot be debited directly from your account.

Entering your contact details is not compulsory, but will assist us if we need to contact you.

Share Purchase Plan Application Form

X 9999999991

I ND

STEP 1

Registration Name & Offer Details

Registration Name: MR SAM SAMPLE
123 SAMPLE STREET
SAMPLETOWN VIC 3000

For your security keep your SRN/
HIN confidential.

Entitlement No: 12345678

Offer Details: Record date: 7.00pm (AEST) 18 June 2014

Minimum value available to purchase: \$1,000

Maximum value available to purchase: \$15,000

STEP 2

Make Your Payment



Bill Code: 99999
Ref No: 1234 5678 9123 4567 89

Pay by Mail:



Make your cheque, bank draft or money order payable to "Simavita Limited" and crossed "Not Negotiable".
Return your cheque with the below payment slip to:

Simavita Limited
C/- Computershare Investor Services Pty Limited
GPO Box 505
Melbourne, VIC, 3001

Contact your financial institution to make your payment from your cheque or savings account.

Privacy Notice

Personal information is collected on this form by Computershare Investor Services Pty Limited ("CIS") for the purpose of maintaining registers of securityholders, facilitating distribution payments and other corporate actions and communications. In addition, the Company may authorise us on their behalf to send you marketing material or include such material in a corporate communication. You may elect not to receive marketing material by contacting CIS using the details provided on the front of this form or emailing privacy@computershare.com.au <<mailto:privacy@computershare.com.au>>. We may be required to collect your personal information under the Corporations Act 2001 (Cth) and ASX Settlement Operating Rules. We may disclose your personal information to our related bodies corporate and to other individuals or companies who assist us in supplying our services or who perform functions on our behalf or to third parties upon direction by the Company where related to their administration of your securityholding, or where you have otherwise agreed we may disclose it. Some of these recipients may be located outside Australia, including in the following countries: Canada, India, New Zealand, the Philippines, the United Kingdom and the United States of America. For further details, including how to access and correct your personal information, and information on our privacy complaints handling procedure, please contact our Privacy Officer at privacy@computershare.com.au <<mailto:privacy@computershare.com.au>> or see our Privacy Policy at <<http://www.computershare.com/au/Pages/default.aspx>>.

Detach here

Purchase Details for Simavita Limited (choose one option)

☐ \$1,000 (2,222 New CDIs) OR ☐ \$2,000 (4,444 New CDIs) OR ☐ \$4,000 (8,889 New CDIs)

☐ \$7,500 (16,667 New CDIs) OR ☐ \$10,000 (22,222 New CDIs) OR ☐ \$15,000 (33,333 New CDIs)



Entitlement No: 12345678

Payment must be received by 5:00pm (AEST) Friday 25th July 2014

MR SAM SAMPLE
123 SAMPLE STREET
SAMPLETOWN VIC 3000

Contact Details

Contact Name _____ Daytime Telephone _____

Cheque Details

Drawer	Cheque Number	BSB Number	Account Number	Amount of Cheque
				A\$

123456789123456789+0000000001-3051+14